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Abstract
The calcium-dependent lectins DC-SIGN and DC-SIGNR (collectively termed DC-SIGN/R) bind to high-mannose carbohydrates on a variety of
viruses. In contrast, the related lectin LSECtin does not recognize mannose-rich glycans and interacts with a more restricted spectrum of viruses.
Here, we analyzed whether these lectins differ in their mode of ligand engagement. LSECtin and DC-SIGNR, which we found to be co-expressed by
liver, lymph node and bone marrow sinusoidal endothelial cells, bound to soluble Ebola virus glycoprotein (EBOV-GP) with comparable affinities.
Similarly, LSECtin, DC-SIGN and the Langerhans cell-specific lectin Langerin readily bound to soluble human immunodeficiency virus type-1
(HIV-1) GP. However, only DC-SIGN captured HIV-1 particles, indicating that binding to soluble GP is not necessarily predictive of binding to
virion-associated GP. Capture of EBOV-GP by LSECtin triggered ligand internalization, suggesting that LSECtin like DC-SIGNmight function as an
antigen uptake receptor. However, the intracellular fate of lectin–ligand complexes might differ. Thus, exposure to low-pH medium, which mimics
the acidic luminal environment in endosomes/lysosomes, released ligand bound to DC-SIGN/R but had no effect on LSECtin interactions with
ligand. Our results reveal important differences between pathogen capture by DC-SIGN/R and LSECtin and hint towards different biological
functions of these lectins.
© 2007 Elsevier Inc. All rights reserved.Keywords: LSECtin; DC-SIGN; HIV; Attachment; Lectin; EbolaIntroduction
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doi:10.1016/j.virol.2007.11.001manner (Cambi et al., 2005; Koppel et al., 2005). Both lectins
recognize high-mannose carbohydrates. In addition, DC-SIGN
binds to Lewis X sugars (Appelmelk et al., 2003; Feinberg et al.,
2001; Guo et al., 2004; Lin et al., 2003; van Die et al., 2003; Van
Liempt et al., 2004). DC-SIGN is expressed by dendritic cells
(DCs) (Geijtenbeek et al., 2000), platelets (Boukour et al., 2006;
Chaipan et al., 2006), activated primary B-cells (He et al., 2006;
Rappocciolo et al., 2006) and certain macrophages (Soilleux
et al., 2001, 2002), whereas DC-SIGNR is found on vascular
Table 1
Reactivity of LSECtin MAbs
ELISA WB FACS IHC Subclasses
D18 + + + + IgG 2a
C 12 + + − n.d. n.d.
D 9 + + − n.d. n.d.
C17 + + − n.d. n.d.
mAb, monoclonal antibody; WB, Western blot; IHC, immunohistochemistry.
190 T. Gramberg et al. / Virology 373 (2008) 189–201endothelium in the placenta and on liver and lymph node sinu-
soidal endothelial cells (Bashirova et al., 2001; Pöhlmann et al.,
2001c). In liver (Lai et al., 2006), lymph node and placenta
(Soilleux et al., 2001, 2002; Pöhlmann et al., 2001c), both lectins
are co-expressed. DC-SIGN and DC-SIGNR (collectively re-
ferred to as DC-SIGN/R) can concentrate virions on the cell
surface, thereby facilitating engagement of the cognate cellular
receptors and subsequent infectious viral entry into target cells.
DC-SIGN-mediated capture of human immunodeficiency
virus type-1 (HIV-1) by DCs in the anogenital mucosa was
roposed to facilitate dissemination of sexually transmitted HIV-1
(Geijtenbeek et al., 2000). However, several reports indicate that
the contribution of DC-SIGN to augmentation of HIV-1
infectivity by DCs is minor (Boggiano et al., 2007; Gummuluru
et al., 2003). Nevertheless, DC-SIGN on platelets or activated B-
cells might promote HIV-1 spread once the virus has reached the
blood stream (Boukour et al., 2006; Chaipan et al., 2006;
Rappocciolo et al., 2006). DC-SIGNR in lymph nodes and liver
might also impact spread of HIV-1 and hepatotropic viruses, like
hepatitis C virus (HCV). Indeed, polymorphisms in the DC-
SIGNR neck region modulate susceptibility to HIV-1 infection
(Liu et al., 2006), and maybe more impressively, a correlation
between the DC-SIGNR genotype and the viral load in HCV
infected patients has been documented (Nattermann et al., 2006).
While the former finding is controversial (Lichterfeld et al., 2003),
the observations that liver sinusoidal endothelial cells (LSEC) are
permissive for HIV-1 infection (Steffan et al., 1992) and capture
HCV envelope protein E2 in a DC-SIGNR-dependent manner
(Lai et al., 2006; Ludwig et al., 2004; Pöhlmann et al., 2003)
indicate that DC-SIGNR and possibly other lectins on LSECs
might impact spread of several clinically relevant human viruses.
The DC-SIGN/R and CD23 genes are located in a cluster of
lectin encoding genes on chromosome 19p13.3 (Soilleux et al.,
2000). Liu and colleagues (2004) reported that the gene for
LSECtin, another calcium-dependent (C-type) lectin, is also
localized in this cluster. They found that LSECtin is co-ex-
pressed with DC-SIGNR in liver and lymph node and, like DC-
SIGN/R, binds to mannose (Liu et al., 2004). We previously
discovered that LSECtin, like DC-SIGN/R, augments Ebola
virus (EBOV) and SARS coronavirus infection (Gramberg et al.,
2005). However, in contrast to DC-SIGN/R, LSECtin failed to
augment HCV and HIV-1 infection and virus interactions with
LSECtin were not inhibited by the mannose polymer mannan
(Gramberg et al., 2005). Thus, LSECtin might have an ex-
pression pattern similar to DC-SIGNR but it seems to interact
with a more restricted spectrum of viruses and seemingly in a
mannose-independent manner. Interestingly, a recent study con-
firmed interactions between LSECtin and EBOV and detected
LSECtin on dendritic cells and macrophages under certain con-
ditions (Dominguez-Soto et al., 2007), suggesting some
similarities between the expression pattern of LSECtin and
DC-SIGN. However, both the natural function and the role of
LSECtin in virus infection are incompletely understood.
Here, we sought to elucidate similarities and differences bet-
ween DC-SIGN/R and LSECtin interactions with ligands in order
to better understand the biological functions of these lectins. We
confirmed co-expression of DC-SIGNR and LSECtin on LSECsand found that both lectins bind to soluble EBOV glycoprotein
(GP) with similar affinities. LSECtin also bound to HIV-1-GP
but failed to capture HIV-1 particles, demonstrating that capture
of soluble GP is not necessarily predictive of virion capture.
Finally, LSECtin like DC-SIGN was able to internalize ligand.
However, ligand bound to LSECtin could not be dissociated by
endosomal low pH, indicating that the intracellular fate of in-
ternalized LSECtin and DC-SIGN might be different.
Results
Generation of LSECtin-specific monoclonal antibodies
In order to investigate LSECtin expression and function, we
generated LSECtin-specific monoclonal antibodies by immuniza-
tion of mice with bacterially expressed LSECtin, followed by
generation of clonal B-cell hybridomas as described previously
(Baribaud et al., 2001). Screening of hybridoma supernatants by
ELISA identified four supernatants that specifically reacted with
the antigen used for immunization. Antibodies from the respective
supernatants were purified. All antibodies were reactive against
recombinantLSECtinas assessedbyELISAandalloweddetection
of both recombinant and cellular LSECtin by Western blot (Table
1; Fig. 1A). However, only the D18 antibody was reactive against
native, cell surface expressed LSECtin as judged by FACS
analysis (Fig. 1A) and was therefore chosen for further analysis.
LSECtin is a type II transmembrane protein, which, based on
sequence analysis, exhibits the following domain structure: N-
terminal cytoplasmic domain (CD), transmembrane domain, neck
domain and C-terminal carbohydrate recognition domain (CRD).
In order to identify the LSECtin domain recognized by D18,
various portions of LSECtin were bacterially produced (Fig. 1B)
and D18 reactivity against the recombinant proteins assessed by
ELISA. D18 specifically reacted with the purified neck domain
and all proteins containing this domain (Fig. 1C), indicating that
the D18 epitope is located in the LSECtin neck region.
DC-SIGNR and LSECtin are co-expressed in liver, lymph node
and bone marrow, but only DC-SIGNR is found in placental
tissue
We next employed D18 to investigate tissue expression of
LSECtin. Immunohistochemical staining of parental 293 cells
and cells engineered to express LSECtin confirmed the speci-
ficity of the antibody (Fig. 2A, B). Staining of tissue sections
revealed no evidence for LSECtin expression in any major
organ/tissue, except lymph node (Fig. 2C, D), liver (Fig. 2G)
and bone marrow (Fig. 2J), where LSECtin was detected with a
Fig. 1. Characterization of the LSECtin-specific monoclonal antibody D18. (A) D18
allows detection of LSECtin by Western blot and FACS analysis. LSECtin was
transiently expressed in 293T cells and expression detected by Western blot (left
panel) or FACS (right panel). Cells transfected with empty vector were analyzed as
negative control. Staining for β-actin served as loading control for the Western blot
analysis. (B) Analysis of recombinant LSECtin variants. Wild-type LSECtin or the
indicated LSECtin domains fused to GSTwere purified from bacteria, separated by
SDS–gel electrophoresis and visualized by Coomassie staining. (C) TheD18 epitope
is located in the LSECtin neck region. The indicated recombinant LSECtin proteins
were coated onto 96-well plates and D18 reactivity against the proteins was analyzed
by ELISA. D18 staining of uncoated control wells and staining with secondary
antibody alone served as negative controls. The results of a representative experiment
are shown and were confirmed in two separate experiments.
191T. Gramberg et al. / Virology 373 (2008) 189–201continuous staining pattern along the sinusoids, in keeping with
expression by sinusoidal endothelial cells rather than Kupffer
cells, which would give a discontinuous staining pattern. Very
similar staining was observed with the DC-SIGN/R-specific
antibody DC28 (Baribaud et al., 2001) (Fig. 2E, H, K) and wasmainly due to DC-SIGNR expression (Bashirova et al., 2001;
Lai et al., 2006; Pöhlmann et al., 2001c). Sinusoidal endothelial
cells in liver (Fig. 2I), but not lymph node (Fig. 2F), also
expressed CLEC-2, a novel HIV-1 attachment factor (Chaipan
et al., 2006). In the liver, anti-LSECtin immunostaining was
more similar to anti-CLEC-2 immunostaining, in keeping with
LSECtin expression by sinus endothelial cells, rather than sinus
endothelial cells and Kupffer cells, which have been reported to
express both DC-SIGN and DC-SIGNR, and DC-SIGN alone,
respectively (Lai et al., 2006). Finally, DC-SIGNR (Fig. 2N),
but not LSECtin (Fig. 2M) or CLEC-2 (Fig. 2O), was expres-
sed by vascular cells in the placenta. Thus, in agreement with
previous results (Liu et al., 2004), LSECtin shows a restricted
tissue expression and is only found in liver, lymph node and
bone marrow sinusoids, where it is co-expressed with DC-
SIGNR. In light of recent published data suggesting expression
of LSECtin by human peripheral blood and thymic dendritic
cells isolated ex vivo (Dominguez-Soto et al., 2007), normal
thymic tissue was immunostained for LSECtin (Fig. 2P). No
positive immunostaining was identified, although DC-SIGN/R
(Fig. 2Q) and CD68 immunostaining (Fig. 2R) demonstrated
the presence of abundant cells of macrophage/dendritic cell
lineage.
LSECtin and the Langerhans cell-specific lectin Langerin bind
to soluble HIV-1 envelope protein but do not capture and
transmit HIV-1
Our previous analyses failed to detect LSECtin interactions
with HIV-1 (Gramberg et al., 2005). It was unclear, however,
whether LSECtin simply failed to bind to the surface unit
Gp120 of the HIV-1 envelope protein or whether the failure to
capture HIV-1 was due to more complex reasons. We therefore
analyzed binding of a soluble HIV-1-Gp120-Fc fusion protein
to CD4-negative HeLa cells transiently expressing DC-SIGN,
LSECtin, Langerin and CD23. Langerin, which is exclusively
expressed by Langerhans cells (Valladeau et al., 1999), was
included as a positive control since we previously showed
robust HIV-1-Gp120 binding to this lectin (Turville et al.,
2002). CD23 served as a negative control. Cell surface ex-
pression of all lectins was readily detectable (Fig. 3A, upper
panel). DC-SIGN and Langerin but not CD23 readily bound to
HIV-1-Gp120 (Fig. 3A, lower panel), as expected (Geijtenbeek
et al., 2000; Turville et al., 2002). To our surprise, LSECtin also
captured HIV-1-Gp120 with high efficiency (Fig. 3A, lower
panel). The mannose polymer mannan blocked binding of HIV-
1-Gp120 and, with slightly lower efficiency, binding of soluble
EBOV-GP-Fc to DC-SIGN and Langerin (Fig. 3B). In contrast,
mannan did not inhibit ligand binding to LSECtin (Fig. 3B),
providing further evidence that LSECtin does not recognize
mannose residues on the surface of ligands. Given the similar
binding of soluble Env by DC-SIGN, LSECtin and Langerin,
we next compared the ability of these lectins to support HIV-1
transfer to target cells (trans-infection). While DC-SIGN-ex-
pressing cells captured and transmitted HIV-1 to target cells with
high efficiency, LSECtin and Langerin-positive cells failed
to bind and transmit HIV-1 (Fig. 4). Langerin expression also
192 T. Gramberg et al. / Virology 373 (2008) 189–201failed to enhance EBOV-GP-driven infection, while DC-SIGN
and LSECtin augmented infection efficiency, as expected
(Gramberg et al., 2005). Finally, all cell lines exhibited com-parable susceptibility to infection with a control virus bearing
the G-protein of vesicular stomatitis virus (VSV-G). Thus,
despite efficient binding to HIV-1-Gp120, LSECtin and
Fig. 3. LSECtin binds to soluble HIV-1-Gp120 in a mannose independent fashion. (A) HeLa cells were transiently transfected with plasmids encoding the
indicated lectins and lectin expression and HIV-1-Gp120 binding analyzed in parallel. Lectin expression was determined by staining with an antibody directed against
a C-terminal AU1 antigenic tag (DC-SIGN, Langerin, CD23) or with the LSECtin-specific monoclonal antibody D18 (top panel). Lectin binding to an HIV-1-Gp120-
Fc fusion protein was assessed by incubating lectin expressing cells with concentrated supernatant containing HIV-1-Gp120 followed by detection of bound protein
with an Fc-specific antibody (bottom panel). Similar results were obtained in two separate experiments. (B) Inhibition of HIV-1-Gp120 binding by mannan. Binding of
HIV-1-Gp120 to lectin expressing cells was analyzed as described for panel (A); however, cells were pre-incubated with PBS or mannan before addition of soluble
envelope protein. Binding to lectin expressing cells in the absence of inhibitor was set as 100%. The results of a representative experiment are shown and were
confirmed in two independent experiments.
193T. Gramberg et al. / Virology 373 (2008) 189–201Langerin do not interact with HIV-1, at least under the conditions
tested and thus may not support HIV-1 spread in infected
patients.
LSECtin and DC-SIGNR bind to soluble EBOV-GP with
similar affinities
Liver and lymph nodes are important early targets of EBOV
infection (Geisbert et al., 2003a). In these tissues, LSECtin and
DC-SIGNR are co-expressed on sinusoidal endothelial cells
and both lectins are capable of augmenting infectious cellularFig. 2. LSECtin is co-expressed with DC-SIGNR on liver, lymph node and bonemarro
REx cells was induced by doxycycline (A) or PBS (B) and the cells were subsequen
Nuclei were stained with hematoxylin (blue). Lymph node was immunostained (bro
immunostained for LSECtin (G), DC-SIGN/R (H) and CLEC-2 (I) demonstrated a c
indicative of expression of all threemolecules by sinusoidal endothelial cells. Serial sec
SIGN/R (arrows on K), but not CLEC-2 (L) on sinusoidal endothelial cells. DC-SIGN
cell types, whereas CLEC-2 was expressed by megakaryocytes only (arrows on L
demonstrated DC-SIGN/R expression by vascular endothelial cells (arrows on N) a
expression of LSECtin (P), although abundant macrophages/dendritic cells were dementry of EBOV (Alvarez et al., 2002; Bashirova et al., 2001;
Pöhlmann et al., 2001c; Simmons et al., 2003). Because DC-
SIGN/R and LSECtin differ in their carbohydrate specificities
(Gramberg et al., 2005), we asked if these differences translate
into different affinities for EBOV-GP, which might have
important implications for EBOVattachment to liver and lymph
node sinusoidal endothelial cells. In order to assess affinities of
LSECtin and DC-SIGNR for EBOV-GP, 293 cells expressing
roughly comparable amounts of these lectins (Fig. 5A) were
incubated with purified soluble EBOV-GP-Fc fusion protein and
binding was assessed by flow cytometry (Fig. 5B). Quantificationw sinusoidal endothelial cells. Expression of LSECtin on stably transfected 293T-
tly formalin fixed, paraffin embedded and immunostained (brown) for LSECtin.
wn) for LSECtin (C and D), DC-SIGN/R (E) and CLEC-2 (F). Liver sections
ontinuous staining pattern around hepatic sinusoids for all the lectin molecules,
tions of bonemarrow demonstrated expression of LSECtin (arrows on J) andDC-
was also expressed by somemegakaryocytes (K) and possibly other bonemarrow
). Sections of placenta were negative for LSECtin (M) and CLEC-2 (O) but
nd DC-SIGN expression by Hofbauer cells (N). Sections of thymus showed no
onstrated by immunostaining for DC-SIGN/R (Q) and CD68 (R).
Fig. 4. LSECtin does not capture and transmit HIV-1 to target cells. HeLa cells
transiently expressing the indicated lectins or control transfected cells were
pulsed with HIV-1 or HIV-1 pseudotypes bearing EBOV-GP or VSV-G. All
viruses encoded the luciferase gene in place of nef. In order to determine HIV-1
binding, the cells were washed and the amount of p24-antigen in cell lysates
determined (top panel). Results are shown as percent of recovered input antigen.
HIV-1 transmission was assessed by coculture of virus-exposed cells with target
cells followed by measurement of luciferase activities in culture lysates (second
panel). The efficiency of EBOV-GP and VSV-G-driven infection was
determined by quantifying luciferase activities in the lysates of infected HeLa
cells (third and fourth panel). The results of representative experiments carried
out in triplicate are presented. Error bars indicate standard deviation (SD).
Similar results were obtained in two independent experiments.
194 T. Gramberg et al. / Virology 373 (2008) 189–201of binding efficiency and assessment of KD values employing a
previously described method (Lozach et al., 2003) revealed
comparable high affinity binding for LSECtin (KD=21 nM) and
DC-SIGNR (KD=26 nM) (Fig. 5C). Thus, LSECtin and DC-
SIGNR on liver and lymph node sinusoidal endothelial cells
might be equally adept at capturing soluble EBOV-GP and pos-
sibly EBOV particles.
LSECtin internalizes soluble EBOV-GP and acidic pH does not
dissolve the lectin–ligand complex
DC-SIGN internalizes ligand for intracellular processing and
subsequent MHC presentation (Engering et al., 2002). We in-
vestigated whether LSECtin was also capable of ligand internaliza-
tion. B-THP cells (Wu et al., 2004) expressing exogenous DC-
SIGN or LSECtin, but not control B-THP cells, readily captured
soluble Alexa-labeled EBOV-GP. Binding was lectin dependent
because a cell population double positive for lectin and EBOV-GP
was readily detectable by flow cytometry. The population of double
positive B-THP LSECtin cells was relatively heterogeneous and
less prominent than that observed with B-THP DC-SIGN cells due
to reduced expression of LSECtin relative toDC-SIGN.When cells
were maintained at 4 °C, EBOV-GP binding could be abrogated by
trypsin digestion, which cleaved both DC-SIGN and LSECtin
(Fig. 6A and data not shown, the remaining LSECtin signal was
most likely due to unspecific reactivity of B-THP LSECtin cells
with antibodies; T.G. and S.P., unpublished observations), sug-
gesting that EBOV-GPwas localized to the cell surface under these
conditions. In contrast, shifting cells to 37 °C for 5 or 15min before
trypsin digestion abrogated lectin expression but preserved the
EBOV-GP signal, indicating that the soluble protein had been
internalized. After successful cellular uptake, the lectin–ligand
complexes might be dissociated by low pH in endosomal com-
partments. Alternatively, the complexes might remain stable at low
pH and might traffic to lysosomes. In order to distinguish bet-
ween these possibilities, we assessed whether exposure to low
pH released EBOV-GP from DC-SIGN/R and LSECtin express-
ing T-REx cells. At neutral pH, all lectin expressing cells bound to
EBOV-GP with comparable efficiency (data not shown). Upon
treatment with medium of pH 6.0 or lower, EBOV-GP was re-
leased from DC-SIGN/R, with the association of DC-SIGNR with
ligand being slightly more resistant to low pH than DC-SIGN–
ligand complexes (Fig. 6B). In contrast, even exposure to pH 5.5
did not dissolve LSECtin–EBOV-GP complexes (Fig. 6B), sug-
gesting that intact LSECtin–ligand complexes might traffic to
lysosomes.
Discussion
We generated and employed an LSECtin-specific mono-
clonal antibody to analyze LSECtin expression and function.
We show that LSECtin is co-expressed with DC-SIGNR on
liver, lymph node and bone marrow sinusoidal endothelial cells
but, unlike DC-SIGNR, is absent from vascular endothelial cells
in the placenta. LSECtin bound to soluble dimeric EBOV-GP
and HIV-1-GP and enhanced EBOV-GP-driven entry. However,
LSECtin failed to capture and transmit HIV-1 to target cells,
Fig. 5. LSECtin and DC-SIGNR exhibit similar affinities for EBOV-GP. 293T-REx cells (Pöhlmann et al., 2001a,b; Simmons et al., 2003) were induced to express
comparable amounts of LSECtin or DC-SIGNR, incubated with the indicated amounts of purified soluble EBOV-GP-Fc fusion protein and binding determined by
FACS. Results of a representative experiment are shown in (A, lectin expression) and (B, GP binding). The average of four independent experiments, for which the
relative geometric mean channel fluorescence values were determined, is shown in panel C. Geometric mean values observed under saturating conditions were set as
100%. Error bars indicate standard deviation. The results were used to calculate KD values employing a previously described method (Lozach et al., 2003).
195T. Gramberg et al. / Virology 373 (2008) 189–201suggesting that LSECtin does not interact with trimeric virion-
associated HIV-1-GP. Binding of EBOV-GP to LSECtin trig-
gered internalization and lectin–ligand complexes remained
stable at low pH, indicating that intact LSECtin–ligand com-
plexes might be transported into lysosomes. Thus, LSECtin
like DC-SIGN might function as an antigen uptake receptor,
but the intracellular fate of their ligands might be different.
Notably, LSECtin has different specificities for virus interac-
tions compared to DC-SIGN and whether it might promote cis-
or trans-infection of other viruses remains to be determined. The
LSECtin-specific antibody we have developed will be an im-
portant tool in these analyses.
This antibody recognized cell surface expressed LSECtin
through an epitope present in the LSECtin neck region (Fig. 1)but did not appreciably diminish EBOV-GP interactions with
LSECtin (data not shown), which occur via the CRD. Staining
of tissue sections revealed that LSECtin and DC-SIGNR are co-
expressed by liver, lymph node and bone marrow sinusoidal
endothelial cells (Fig. 2), which is in agreement with a previous
report (Liu et al., 2004). LSECs are exposed to blood from the
systemic circulation and from the gut and exhibit powerful sca-
venger capabilities (Lalor et al., 2006). Lectins like mannose
receptor (MR), DC-SIGNR and LSECtin might contribute to the
scavenger function of LSECs (Lalor et al., 2006). Whether the
interaction of these lectins with viruses present in the blood stream
preferentially leads to viral uptake, processing and MHC pre-
sentation or augmentation of viral infectivity remains to be de-
termined. Notably, LSECs are permissive for HIV-1 infection
Fig. 6. LSECtin internalizes EBOV-GP and lectin–ligand complexes are not dissolved by low pH. (A) LSECtin internalizes ligand. B-THP cells engineered to express
DC-SIGN or LSECtin or control B-THP cells (Wu et al., 2004) were incubated with Alexa647-labeled soluble EBOV-GP-Fc fusion protein on ice; subsequently, cells
were kept on ice or shifted to 37 °C for 5 min or 15 min to allow internalization of bound antigen. After trypsin or control treatment lectin expression and EBOV-GP
binding were analyzed. The results of a representative experiment are shown and were confirmed in two separate experiments. (B) Lysosomal pH does not dissociate
LSECtin–ligand complexes. 293T-REx cells induced to express comparable amounts of the indicated lectins were incubated with soluble EBOV-GP-Fc fusion protein,
unbound protein was washed away and the cells were treated for 20 min with media adjusted to the indicated pH values. Bound protein was detected by FACS analysis.
Binding at pH 7.5 was set as 100%. The results of a representative experiment are presented and were confirmed in three independent experiments.
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197T. Gramberg et al. / Virology 373 (2008) 189–201(Steffan et al., 1992) and polymorphisms in the DC-SIGNR
neck region might impact susceptibility to HIV infection (Liu
et al., 2006).Moreover, LSECs capture HCVenvelope protein via
DC-SIGNR (Lai et al., 2006; Ludwig et al., 2004) and certain
variations in the DC-SIGNR neck region are associated with a
reduced viral load in HCV patients (Nattermann et al., 2006).
Thus, DC-SIGNR on LSECs and lymph node and bone marrow
sinusoidal endothelium might promote HIV-1 and particularly
HCV infection. By contrast, LSECtin does not interact with these
viruses but our cell culture data indicate that LSECtin could
facilitate filovirus interactions with sinusoidal endothelium in
liver, lymph node and bone marrow. Potentially increased ex-
pression of LSECtin due to elevated cytokine production in the
context of EBOV infection might facilitate these interactions.
Liver and particularly lymph nodes are prominent early targets of
EBOV in experimentally infected macaques, whereas infection
of bone marrow is observed at later stages (Geisbert et al., 2003a,
b). Because infection of the vascular endothelium in these or-
gans is only detected during the later stages of EBOV replica-
tion (Geisbert et al., 2003b), one might postulate that LSECtin
and DC-SIGNR mainly promote viral spread by virus capture
and transmission to adjacent target cells, like hepatocytes or
Kupffer cells. In fact, LSECs can bind and transmit duck hepati-
tis B virus to adjacent hepatocytes but do not become infected
themselves (Breiner et al., 2001), suggesting that these cells, like
DCs, might promote viral infection in trans.
LSECtin did not bind or transmit HIV-1 (Fig. 4), which is in
agreement with our previous results (Gramberg et al., 2005).
However, LSECtin captured a soluble HIV-1 Gp120-Fc fusion
protein with high efficiency (Fig. 3), suggesting that the binding
interface present in soluble Gp120 is obscured or absent in Env
trimers on HIV-1 particles. Notably, similar results were obtained
with Langerin (Figs. 3 and 4), a C-type lectin specifically expressed
on Langerhans cells (Valladeau et al., 1999), probably the first cell
type to come into contact with sexually transmitted HIV-1. The
discrepancy between Gp120 and virion binding by LSECtin
indicates that soluble and virion-associated Gp120 might differ in
terms of content and/or surface exposure of glycans. Alternatively,
the multimerization status of Gp120 (soluble Fc fusion protein is
most likely dimeric while virion-associated protein is trimeric) or
the lectin expression level might play a role. For Langerin, the
situation might be different because it has recently been proposed
that Langerin efficiently captures HIV-1 and targets bound virions
for degradation in intracellular compartments (de Witte et al.,
2007). In light of these results, our finding that Langerin expressing
HeLa cells did not capture HIV-1 can be explained in three ways.
Exogenous Langerin on HeLa cells, unlike endogenous Langerin
onLangerhans cells,might not be capable of bindingHIV-1,maybe
because a cofactor present on Langerhans cells is missing. Alter-
natively, as for LSECtin, lectin expression levels might play a role.
Thus, higher copy numbers of surface expressed Langerin might
be required for binding to HIV-1 as compared to binding to soluble
gp120. In this context, it needs to be pointed out that Langerhans
cells most likely express substantially higher levels of Langerin
relative to the transfected cells used in the present study. Finally,
Langerin-boundHIV-1might be rapidly endocytosed and degraded
in HeLa cells. However, the absence of any specific HIV-1 bindingto Langerin expressing HeLa and 293T cells even early after
exposure (Fig. 4 and data not shown) suggests that HIV-1 de-
gradation might not account for the effects observed. In any case,
it is notable that binding to soluble Gp120 is not necessarily
predictive for binding to virus particles (present manuscript) and
capture of virions does not necessarily result in transmission
(Baribaud et al., 2001; Pöhlmann et al., 2001b). Detailed analysis
of the determinants involved might yield important insights into
the molecular mechanisms behind lectin-mediated augmentation
of viral infectivity.
Ligand captured by DC-SIGN, but not DC-SIGNR (Guo
et al., 2004), is endocytosed and transported into late endo-
somes/lysosomes (Engering et al., 2002). The acidic milieu
in this compartment dissociates the lectin–ligand complex and
DC-SIGN might be recycled to the cell surface (Engering et al.,
2002). Soluble EBOV glycoprotein bound to LSECtin ex-
pressing cells at 37 °C but not at 4 °C was protected against
protease digestion (Fig. 6A), suggesting that LSECtin–ligand
complexes were also endocytosed. A recent study by Dom-
inguez-Soto and colleagues (2007) confirms and extends this
observation by showing that tyrosine- and diglutamic-contain-
ing motifs in the cytoplasmic domain mediate rapid LSECtin
internalization. LSECtin like DC-SIGN might therefore func-
tion as an antigen uptake receptor. However, the fate of the
endocytosed lectins might be different. Low pH dissociated
DC-SIGN/R–ligand complexes, whereas LSECtin–ligand com-
plexes remained stable, even in an acidic milieu similar to that
observed in lysosomes (Fig. 6B). Thus, both LSECtin and
ligand might be degraded in lysosomes whereas DC-SIGN
might be recycled to the cell surface. Obviously, EBOVescapes
degradation upon LSECtin-mediated uptake and uses this lectin
for augmentation of infectivity (Fig. 4; Gramberg et al., 2005).
These results are not unexpected because endosomal/lysosomal
enzymes were shown to dissociate GP1 (which is bound by
LSECtin) from GP2 (which drives membrane fusion) (Chan-
dran et al., 2005; Schornberg et al., 2006), thereby most likely
releasing EBOV from LSECtin and allowing the virus to fuse
with the vesicle membrane.
In summary, LSECtin shows important similarities to DC-
SIGN/R, including expression by liver, lymph node and bone
marrow sinusoidal endothelial cells, interaction with viral glyco-
proteins and internalization of bound ligands. However, impor-
tant differences are also apparent. For one, LSECtin promotes
infection by a more restricted spectrum of viruses and might have
no impact on HIV-1 and HCV spread in infected individuals.
Secondly, complexes between ligand and DC-SIGN/R but not
LSECtin–ligand complexes are dissociated by a low pH milieu,




293T cells were propagated in Dulbecco's modified Eagle's
medium (DMEM) with 10% fetal bovine serum (FBS), peni-
cillin and streptomycin. 293T-REx cells expressing DC-SIGN,
198 T. Gramberg et al. / Virology 373 (2008) 189–201DC-SIGNR or LSECtin were described previously (Gramberg
et al., 2005; Pöhlmann et al., 2001a,b; Simmons et al., 2003) and
maintained in medium containing DMEM, 10% FBS, 50 μg/ml
zeocin (Invitrogen, CA, USA), 2.5 μg/ml of blasticidin (In-
vitrogen, CA, USA), penicillin and streptomycin. Expression
was induced by culturing the cells in medium containing 0.1 μg/
ml of doxycycline (Sigma-Aldrich, Germany). 293T-REx pa-
rental cells were maintained in the same medium as lectin ex-
pressing cell lines; however, no zeocin was added. CEMx174
5.25 (Hsu et al., 2003) and HeLa cells were maintained in RPMI
1640 containing 10% FBS, penicillin and streptomycin. Paren-
tal B-THP cells, which are derived from Raji-B-cells (Wu et al.,
2004), and B-THP cells expressing DC-SIGN and DC-SIGNR
were maintained in RPMI 1640 containing 10% FBS, penicil-
lin and streptomycin. B-THP cells expressing LSECtin were
generated via electroporation and FACS sorting and were main-
tained in RPMI 1640 supplemented with 10% FBS, penicillin,
streptomycin and 500 μg/ml G418. All cells were grown at 37 °C
and 5% CO2.
Plasmid construction and in vitro mutagenesis
Expression plasmids encoding the indicated lectins were
described previously (Pöhlmann et al., 2001a,b; Simmons et al.,
2003). The glycoprotein (GP) expression plasmids employed
for the generation of pseudotyped viruses were also described
previously (Simmons et al., 2003). For regulated lectin ex-
pression, the open reading frames (ORFs) were inserted into
pcDNA4TO (Invitrogen, CA, USA) as described previously
(Gramberg et al., 2005; Marzi et al., 2004). For expression of
soluble EBOV-GP and soluble HIV-1 Gp120, the extracellular
portion of the respective GP-ORF was fused to the Fc part of
human IgG1 via PCR and cloned in frame with the amino-
terminal murine IgG kappa signal peptide in the eukaryotic
expression vector pAB61, as described (Gramberg et al., 2005;
Marzi et al., 2004). For prokaryotic expression of LSECtin,
PCR fragments spanning the entire LSECtin ORF or sequen-
ces encoding the indicated protein domains were inserted into
pGEX6P1 (Amersham Biosciences, UK) via BamHI and XhoI.
All PCR-amplified sequences were confirmed by automated
sequence analysis.
Antigens and antisera
A mouse monoclonal antibody (MAb) directed against the
AU1 antigenic tag was purchased from Covance Research
Products, CA, USA. The MAbs 507 (DC-SIGN specific), 526,
DC28, DCN46 (DC-SIGN/R specific) and 604 (directed against
DC-SIGNR) were obtained via the NIH AIDS Research and
Reference Reagent Programme. FITC-conjugated anti-mouse
and Cy5-conjugated anti human secondary antibodies were
purchased from Jackson ImmunoResearch, PA, USA, and Dia-
ova, Germany, respectively. The anti-LSECtin antibodies D18,
C12, D9 and C17 were obtained by immunizing NMRI mice
with 20 μg of purified GST–LSECtin fusion protein, as de-
scribed elsewhere (Gramberg et al., 2005). Fusion proteins were
obtained by overexpression in Escherichia coli DH10B fol-lowed by purification of the proteins employing Glutathione
Sepharose 4B Beads (Amersham Biosciences, UK). After a
final boost, splenocytes were removed from immunized mice
and fused with SP 2.0 myeloma cells. Clonal hybridoma cells
were cultured in HAT selection medium and screened for anti
LSECtin reactivity via enzyme-linked immunosorbent assay
(ELISA), Western blot analysis and flow cytometry. Subse-
quently, antibodies were purified from supernatants reactive
in Western blot (C12, D9, C17) or flow cytometry (D18) via
HighTrap™ProteinG-Columns (Amersham Biosciences)
according to the manufacturers instructions.
Binding of soluble glycoproteins to lectin expressing cells
Soluble EBOV-GP-Fc and HIV-1-Gp120-Fc fusion proteins or
control Fc were obtained by harvesting the supernatant of 293T
cells 48 h after transient transfection with the respective expres-
sion vectors. The supernatants containing the respective proteins
were concentrated using Centricon Plus-20 centrifugal filters
(Millipore, USA). To measure lectin binding, we incubated com-
parable amounts of soluble protein, as judged by Western blot,
with transiently transfected HeLa cells for 45 min on ice. After
washing with FACS buffer, cells were stained with Cy5-conjuga-
ted anti-human IgG (Jackson ImmunoResearch, USA) at a final
concentration of 15 μg/ml for 45 min on ice. Cells were then
washed and diluted in FACS buffer and binding was measured via
flow cytometry using a FACS-Calibur flow cytometer (Becton
Dickinson). To determine the pH dependence of GP binding, we
inoculated lectin expressing 293 cells with the indicated solu-
ble GPs and subsequently incubated for 20 min in ice-cold PBS
(pH 5.0–7.5). Staining with secondary antibody and detection via
flow cytometry was performed as described above.
Internalization assay
Soluble EBOV-GP-Fcwas directly labeledwith theAlexa647-
fluorochrome using the AlexaFluor647-labeling Kit (Invitro-
gen, CA, USA). To assess internalization, we incubated lectin
expressing B-THP cells with labeled protein on ice, washed and
incubated at 37 °C or on ice, respectively. After fixation of the
cells with 2% PFA (10 min/ice), surface molecules were cleaved
off by treatment with 1mg/ml trypsin TPCK (Invitrogen). Sub-
sequently, cells were stained for lectin expression on ice (lectin-
specific antibody, Cy3-labeled secondary antibody) and were
analyzed via flow cytometry, as mentioned above.
Production of reporter viruses and infection assays
HIV-1-derived pseudotypes were generated by co-transfec-
tion of 293T cells with GP expression plasmids coding for the
indicated glycoproteins and pNL4-3 E−R−Luc plasmid, as
described previously (Connor et al., 1995; Simmons et al.,
2003). The production of replication competent HIV-1 NL4-3
reporter virus bearing the luciferase gene in place of nef has
been described previously (Pöhlmann et al., 2001a). The culture
supernatants were harvested 48 h after transfection, passed
through 0.4 μm pore size filters, aliquoted and stored at −80 °C.
199T. Gramberg et al. / Virology 373 (2008) 189–201To assess lectin-mediated enhancement of infection, we see-
ded 293 cells or HeLa cells expressing the indicated lectins
onto 96-well plates at a density of 1.0×104 cells per well and
incubated with viral supernatants normalized for comparable
luciferase activity upon infection of control cells. Generally, the
medium was replaced 12 h after infection and luciferase ac-
tivities in culture lysates were determined 72 h after infection
with a commercially available kit, following the recommenda-
tions of the manufacturer (Promega, WI, USA).
HIV-1 binding and transmission assays
HeLa cells transiently expressing the indicated lectins were
seeded onto 96-well plates and incubated with HIV-1 NL4-3
reporter virus normalized for capsid protein (p24) content by
ELISA (Murex, Abbott Diagnostics, IL, USA). After 3 h incu-
bation at 37 °C, the cells were washed three times with PBS and
either lysed in 1% Triton X-100 followed by quantification of
the amount of bound virus by p24-ELISA or cocultured with
CEMx174 5.25 cells. Luciferase activities in cell lysates were
determined 72 h after cocultivation as described above.
Assessment of KD values
To compare the affinities of LSECtin and DC-SIGNR for
ligand, we determined the dissociation constant KD of both
proteins for binding to soluble EBOV-GP-Fc. To this end, we
incubated 3×105 293T-Rex cells (Invitrogen, CA, USA)
induced to express comparable amounts of DC-SIGNR and
LSECtin with indicated amounts of soluble EBOV-GP-Fc (0–
15 μg/ml) or control-Fc (0–15 μg/ml) for 45 min on ice. Pilot
experiments showed saturation binding upon incubation of cells
with 15 μg/ml soluble EBOV-GP-Fc (data not shown). After
washing with FACS buffer, cells were stained with Cy5-con-
jugated secondary antibody for 45 min on ice. Cells were then
washed and diluted in FACS buffer and binding was measured
via flow cytometry. After subtracting unspecific binding, spe-
cific binding curves were fit in by non-linear regression. KD
values were calculated by the use of the Origin 6.0 software
(Microcal Software, USA), following a previously described
protocol (Lozach et al., 2003).
ELISA reactivity of anti LSECtin MAbs
To determine the reactivity and domain specificity of anti-
LSECtin antibodies, we coated 1.5 μg/ml of the indicated GST-
fusion proteins or GST-control protein onto 96-well ELISA
plates. After blocking free binding sites with blocking buffer
(TBS buffer+2% BSA), coated fusion proteins were incubated
with 100 ng/μl of the indicated anti LSECtin antibodies or a
control antibody for 2 h at room temperature. After extensive
washing, specific interactions of the LSECtin–MAbs with fusion
proteins were assessed by measuring the reactivity of alkaline
phosphatase bound to secondary antibody (Vector-Laboratories,
USA) with 5 mM p-nitrophenylphosphate (Vector Labs, USA) in
an ELISA plate reader (SpectraMAX 190, Molecular Devices,
USA) at 405 nm.Immunostaining of tissue sections
Expression of LSECtin on 293T-REx cells was induced by
doxycycline or PBS, the cells were pelleted, fixed in formalin,
embedded in paraffin wax and immunostained as described for
tissues. Tissue microarrays (a generous gift from Professor Kevin
Gatter, University of Oxford) and anonymised sections of a range
of normal tissues were obtained from the Department of Cellular
Pathology, John Radcliffe Hospital, Oxford, United Kingdom,
with local Research Ethics Committee approval. These samples
were immunostained as described previously (Pöhlmann et al.,
2001c) with mouse monoclonal anti-LSECtin or isotype-matched
negative control, mouse MAb DC28, mouse MAb CD68 clone
PGM1 (Dako) or goat polyclonal anti-CLEC-2 (R&D Systems)
and detected using standard staining kits from Dako and Vec-
tor Laboratories. All sections were carefully reviewed by an
experienced histopathologist (E.S.). Images were taken at room
temperature with an Olympus BX40 microscope equipped with
a 40/0.75 0.17 lens and a Nikon Coolpix 950 digital camera.
Images were analyzed with Adobe Photoshop version 7 software.
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